IP Library › Granted Patent US 9,533,967
Granted Patent B2
US 9,533,967 · App. 13/630,201 · Granted Jan 3, 2017

Multisubstituted aromatic compounds as inhibitors of thrombin

Inventors: Kevin Michael Short (Fremont, CA); Son Minh Pham (Fremont, CA); David Charles Williams (Fremont, CA); Somalee Datta (Sunnyvale, CA)
Assignee: VERSEON CORPORATION
C07D401/04A61K31/4427A61K31/4439C07D405/14C07D409/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,533,967
App. No.
13/630,201
Granted
Jan 3, 2017
Kind
B2
Abstract

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

Claims (180)

1. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is —NR 5 —;

L 2 is a bond;

L 3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

L 4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

R 1 is substituted alkyl, wherein the substituted alkyl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of oxo, —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted heteroaryl group has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl.

2. The compound according to claim 1 , wherein L 3 is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R 3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

3. The compound according to claim 1 , wherein L 3 is a bond, —NH—, —NHCH 2 —or —NH(CH 2 ) 2 —.

4. The compound according to claim 1 , wherein L 4 is a bond; and R 4 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

5. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;

L 2 is a bond;

L 3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

L 4 is a bond;

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of oxo, —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted heteroaryl group has one or more substituent selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is unsubstituted alkyl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl;

provided that:

L 1 is a bond, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,

when L 1 is a substituted or unsubstituted alkylene, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

when L 1 is —S—or substituted or unsubstituted heteroalkylene wherein the heteroatom is S, R 1 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

6. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable excipient.

7. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;

L 2 is a bond;

L 3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

L 4 is a bond; substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of oxo, —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 3 is substituted or unsubstituted heteroaryl, wherein the substituted heteroaryl group has one or more substituent selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl;

provided that:

L 1 is a bond, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl,

when L 1 is a substituted or unsubstituted alkylene, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

when L 1 is —S—or substituted or unsubstituted heteroalkylene wherein the heteroatom is S, R 1 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

8. The compound according to claim 7 , wherein said R 3 substituted or unsubstituted heteroaryl contains nitrogen as a heteroatom.

9. The compound according to claim 8 , wherein R 3 is substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substitute or unsubstituted pyridyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted purinyl, substituted or unsubstituted indolyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted isoquinolinyl, substituted or unsubstituted triazolyl, or substituted or unsubstituted tetrazolyl.

10. The compound according to claim 1 , wherein said R 1 substituted alkyl group is substituted with one or more aryl or heteroaryl groups.

11. The compound according to claim 10 , wherein said R 1 substituted alkyl group is substituted with one or more aryl or heteroaryl groups substituted with one or more halogens.

12. The compound according to claim 1 , wherein L 3 is a bond, or substituted or unsubstituted alkylene, and R 3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

13. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;

L 2 is a bond;

L 3 is —C(O)O—;

L 4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of oxo, —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 3 is substituted or unsubstituted alkyl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl;

provided that:

L 1 is a bond, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl,

when L 1 is a substituted or unsubstituted alkylene, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

when L 1 is —S—or substituted or unsubstituted heteroalkylene wherein the heteroatom is S, R 1 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

14. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;

L 2 is a bond;

L 3 —C(O)NR 6 , where R 6 is hydrogen or akyl;

L 4 is a bond; substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, substituted cycloalkenyl, substituted heterocycloalkyl, substituted heterocycloalkenyl, substituted fused ring aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of oxo, —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl;

R 3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl;

provided that:

L 1 is a bond, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl,

when L 1 is a substituted or unsubstituted alkylene, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

when L 1 is —S—or substituted or unsubstituted heteroalkylene wherein the heteroatom is S, R 1 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

15. The compound according to claim 1 , wherein R 3 is substituted or unsubstituted phenyl or substituted or unsubstituted pyridyl.

16. The compound according to claim 7 , wherein L 1 is —S—, —NR 5 , substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene, and R 1 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or unsubstituted heterocycloalkyl.

17. The compound according to claim 1 , wherein R 2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heterocycloalkenyl.

18. The compound according to claim 1 , wherein R 2 is substituted or unsubstituted heteroaryl.

19. The compound according to claim 18 , wherein R 2 is substituted or unsubstituted furyl, substituted or unsubstituted thienyl, or substituted or unsubstituted pyridyl.

20. A compound with structure of the following formula:

or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof;

wherein:

L 1 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —NHSO 2 —, or —NR 5 —;

L 2 is a bond;

L 3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

L 4 is a bond; substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO 2 —, —O—, —NHSO 2 —, or —NR 5 —;

R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl having at least one heteroatom selected from the group consisting of N, P, Si, and S, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl has one or more substituent group selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , oxo, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 2 is substituted or unsubstituted fused ring aryl;

R 3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein the substituted heteroaryl group has one or more substituent selected from the group consisting of —OH, —NH 2 , —SH, —CN, —CF 3 , —NO 2 , halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted aryl, or substituted or unsubstituted heteroaryl; and

R 5 is hydrogen, or substituted or unsubstituted alkyl;

provided that:

L 1 is a bond, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl,

when L 1 is a substituted or unsubstituted alkylene, R 1 is substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

when L 1 is —S—or substituted or unsubstituted heteroalkylene wherein the heteroatom is S, R 1 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

21. The compound according to claim 20 , wherein R 2 is substituted or unsubstituted naphthyl.

22. The compound according to claim 1 , wherein said compound is selected from the group consisting of:

Compound 41, 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 103, 1-[(2-amino-4-methoxyphenyl)carbonyl]-N-benzyl-3-(2-fluorophenyl)-1H-pyrazol-5-amine;

Compound 105, 1-[(2-amino-4-methoxyphenyl)carbonyl]-N-benzyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 106, 1-[(2-amino-4-methylphenyl)carbonyl]-N-benzyl-3-(2-fluorophenyl)-1H-pyrazol-5-amine;

Compound 108, 1-[(2-amino-4-methylphenyl)carbonyl]-N-benzyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 114, 1-[(2-chlorophenyl)carbonyl]-N-[(4-fluorophenyl)methyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 116, 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine;

Compound 118, 1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-N-(thiophen-3-ylmethyl)-1H-pyrazol-5-amine;

Compound 201, N-(furan-2-ylmethyl)-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 202, N-(furan-3-ylmethyl)-1-[( 2 -methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 208, N-[(4-fluorophenyl)methyl]-1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 234, N-benzyl-1-[(2,4-dimethoxyphenyl)carbonyl]-3-(2-fluorophenyl)-1H-pyrazol-5-amine;

Compound 236, N-benzyl-1-[(2,4-dimethoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 241, N-benzyl-1-[(2-bromophenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 242, N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(2-fluorophenyl)-1H-pyrazol-5-amine;

Compound 244, N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 247, N-benzyl-1-[(2-ethylphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 251, N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 256, N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 260, N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 270, N-benzyl-1-[(naphthalen-1-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 272, N-benzyl-1-[(naphthalen-2-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 276, N-benzyl-1-[2-(propan-2-yl)phenyl]carbonyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

Compound 277, N-benzyl-3-(2-fluorophenyl)-1-[(2-fluorophenyl)carbonyl]-1H-pyrazol-5-amine;

Compound 278, N-benzyl-3-(2-fluorophenyl)-1-[(2-methoxyphenyl)carbonyl]-1H-pyrazol-5-amine;

Compound 279 N-benzyl-3-(2-fluorophenyl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 284, N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 609, 2-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 613, 2-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 625, 3-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 629, 3-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 641, 4-[5-(benzylamino)-3-(pyridin-3-yl)-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 645, 4-[5-(benzylamino)-3-phenyl-1H-pyrazol-1-yl]carbonylbenzonitrile;

Compound 648, N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 650, N-benzyl-1-[(2-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 652, N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 655, N-benzyl-1-[(2-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 656, N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 657, N-benzyl-1-[(2-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 658, N-benzyl-1-[(2-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 662, N-benzyl-1-[(2-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 664, N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 668, N-benzyl-1-[(3-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 670, N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 673, N-benzyl-1-[(3-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 674, N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 678, N-benzyl-1-[(3-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 680, N-benzyl-1-[(3-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 684, N-benzyl-1-[(3-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 686, N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 689, N-benzyl-1-[(4-chlorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 690, N-benzyl-1-[(4-fluorophenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 692, N-benzyl-1-[(4-fluorophenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 693, N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 697, N-benzyl-1-[(4-methoxyphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 699, N-benzyl-1-[(4-methylphenyl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 702, N-benzyl-1-[(4-methylphenyl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 704, N-benzyl-1-[(furan-2-yl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

Compound 706, N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 714, N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 718, N-benzyl-1-[2-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine;

Compound 722, N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 726, N-benzyl-1-[3-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine;

Compound 730, N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

Compound 734, N-benzyl-1-[4-(dimethylamino)phenyl]carbonyl-3-phenyl-1H-pyrazol-5-amine;

Compound 744, N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 746, N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 747, N-benzyl-3-(pyridin-3-yl)-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 750, N-benzyl-3-phenyl-1-[(pyridin-2-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 752, N-benzyl-3-phenyl-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine;

Compound 754, N-benzyl-3-phenyl-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine; and

Compound 755, N-benzyl-3-phenyl-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2020
From: VERSEON CORPORATION
To: VERSEON INTERNATIONAL CORPORATION
Reel/Frame 054145/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: SHORT, KEVIN MICHAEL; PHAM, SON MINH; WILLIAMS, DAVID CHARLES; DATTA, SOMALEE
To: VERSEON CORPORATION
Reel/Frame 030181/0927 →
Continuity (3)
Continuation PCTUS2011030585 · Mar 30, 2011
Provisional Application 61319175 · Mar 30, 2010
Related Publication 20130040950A1 · Feb 14, 2013